Investigation of Pembrolizumab De-Escalation After pCR Aims to Challenge SOC in Early-Stage TNBC

Yuan Yuan, MD, PhD, discusses the OptimICE-pCR trial and other ongoing clinical trials in breast cancer being conducted at Cedars-Sinai, and expands on the role of CDK4/6 inhibitors and other novel treatment strategies for patients with hormone receptor-positive breast cancer.

Related Keywords

California ,United States ,Cathie Chung ,Peterp Lee ,Los Angeles ,Philomena Mcandrew ,Natasha Banerjee ,Yuan ,Breast Oncology Disease Research Group At Cedars ,Sinai Medical Center ,Alliance For Clinical Trials In Oncology Optimice P ,Science Summit ,Breast Medical Oncology Medicine ,Breast Oncology Disease Research Group ,Cedars Sinai Medical Center ,Clinical Trials ,